Home World News FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a... World News FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 458 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Summer Sun Safety Tips September 3, 2020 Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma October 20, 2023 Woman with Breast Cancer May Have Saved Her Twin’s Life by... October 16, 2020 Load more HOT NEWS Talking With Your Doctor About Negative Emotions During Cancer Men’s skin cancer rates increase by 50% over decade Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... Empowering People With Cancer: A Q&A With Cancer.Net Editor in Chief...
